Prescient Therapeutics: Q&A Update with Dr James Campbell
Reach Markets recently interviewed Dr James Campbell regarding his newly appointment position as Non-Executive Chairman.
In this session, Dr James Campbell discusses:
- Why he stepped up as Chair and his focus over the next 12 months.
- Key milestones for PTX-100 as we progress into Phase 2 clinical trials.
- Building a strong, Australia-based team with a focus on cost efficiency that will allow PTX to go deep into Phase 2.
Recorded on 9 April 2025 at 12:00pm (AEST)
Featured Speaker
Dr James Campbell
Non-Executive Chairman
Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies.
He is currently CEO of Patrys Limited, a company developing novel antibody therapeutics for oncology.
He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011. His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale.
Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.
